INNOVADERM CRO IS NOW INDERO.

Systemic Sclerosis Case Study

Indero

Indero

Team of Experts

Author picture

Click here for a PDF version of this case study

Outcomes

  1. Effective study design and patient management leading to high patient retention (only 4% discontinuation).
  2. Patient recruitment was completed on time without any advertisement despite longer timelines associated with academic sites and the institutional burden.

 

Study Characteristics

  • Disease Focus: Systemic Sclerosis (SSc), including subgroups Raynaud’s Phenomenon (RP), Limited cutaneous SSc (lcSSc), and Diffuse cutaneous SSc (dcSSc).
  • Patient Demographics: 49 patients with diverse geographic distribution.
  • Study Design: Biopsy-based research requiring 2 or 4 x 3mm biopsies per patient; no treatment was offered as part of the study.

 

Study Challenges & Solutions

Challenge #1 – Recruitment

The absence of an active treatment arm made the study less appealing to potential participants.

Solution: Leveraged the site’s comprehensive patient database to identify and recruit eligible patients.

 

Challenge #2 – Logistics

  • Many participants traveled long distances for study visits, with some living more than 2h away.
  • Biopsies were conducted at a separate institute, requiring patients to attend 2 locations for each visit.

Solution: Successfully coordinated complex logistics, including transportation support for patients from remote areas and seamless scheduling across multiple facilities.

 

Need help with your next rheumatology study?

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.